Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16128938,pH,"At presumed steady-state (day 7), median 24-h pH values were 5.02 and 4.79 for tenatoprazole and esomeprazole, respectively.",Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16128938/),,5.02,5792,DB00736,Esomeprazole
,16128938,pH,"At presumed steady-state (day 7), median 24-h pH values were 5.02 and 4.79 for tenatoprazole and esomeprazole, respectively.",Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16128938/),,4.79,5793,DB00736,Esomeprazole
,16364049,Cmax,"It was demonstrated that increasing the rate of intravenous infusion of esomeprazole 40 mg resulted in higher Cmax values (geometric means; 5.2-7.6 micromol/l), but the AUC values remained relatively constant (7.1-7.2 micromor/l).",Pharmacokinetics of esomeprazole following varying intravenous administration rates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364049/),[μM] / [l],5.2-7.6,8213,DB00736,Esomeprazole
,16364049,AUC,"It was demonstrated that increasing the rate of intravenous infusion of esomeprazole 40 mg resulted in higher Cmax values (geometric means; 5.2-7.6 micromol/l), but the AUC values remained relatively constant (7.1-7.2 micromor/l).",Pharmacokinetics of esomeprazole following varying intravenous administration rates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364049/),[μmor] / [l],7.1-7.2,8214,DB00736,Esomeprazole
,16364049,Cmax,intravenous injection had lower Cmax (3.6 micromol/l) and AUC (2.9 micromol.r/l) values than any of the infusions of esomeprazole 40 mg.,Pharmacokinetics of esomeprazole following varying intravenous administration rates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364049/),[μM] / [l],3.6,8215,DB00736,Esomeprazole
,16364049,AUC,intravenous injection had lower Cmax (3.6 micromol/l) and AUC (2.9 micromol.r/l) values than any of the infusions of esomeprazole 40 mg.,Pharmacokinetics of esomeprazole following varying intravenous administration rates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364049/),[r·μM] / [l],2.9,8216,DB00736,Esomeprazole
,32110830,concentration,"Patients with no PPI had no significant difference in plasma voriconazole concentration when compared with those with PPI (2.63 ± 2.13 μg/mL [95% confidence interval {CI} 1.57-3.69] vs 2.11 ± 1.73 μg/mL [95%CI 1.67-2.55], P > .05).",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.63,14376,DB00736,Esomeprazole
,32110830,concentration,"Patients with no PPI had no significant difference in plasma voriconazole concentration when compared with those with PPI (2.63 ± 2.13 μg/mL [95% confidence interval {CI} 1.57-3.69] vs 2.11 ± 1.73 μg/mL [95%CI 1.67-2.55], P > .05).",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.11,14377,DB00736,Esomeprazole
,32110830,plasma concentration,"However, voriconazole plasma concentration was significantly lower in patients treated with pantoprazole vs those treated with omeprazole (1.44 ± 1.22 μg/mL [95%CI 0.94-1.94) vs 2.67 ± 1.88 μg/mL [95%CI 2.02-3.32], P = .013) suggesting a greater CYP2C19 enzyme inhibitory effect of omeprazole.",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],1.44,14378,DB00736,Esomeprazole
,32110830,plasma concentration,"However, voriconazole plasma concentration was significantly lower in patients treated with pantoprazole vs those treated with omeprazole (1.44 ± 1.22 μg/mL [95%CI 0.94-1.94) vs 2.67 ± 1.88 μg/mL [95%CI 2.02-3.32], P = .013) suggesting a greater CYP2C19 enzyme inhibitory effect of omeprazole.",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.67,14379,DB00736,Esomeprazole
,20498287,t(max),"Nilotinib t(max) was prolonged from 4.0 to 6.0 hours, but t(1/2) was not altered.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),h,4.0 to 6.0,16195,DB00736,Esomeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,1.0,16196,DB00736,Esomeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,2.79,16197,DB00736,Esomeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,3.98,16198,DB00736,Esomeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.30,16199,DB00736,Esomeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.38,16200,DB00736,Esomeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.31,16201,DB00736,Esomeprazole
,16338182,limit of quantification (LOQ),The limit of quantification (LOQ) achieved with this method was 5 ng/ml for 5-hydroxyomeprazole and 10 ng/ml for omeprazole and omeprazole-sulfone using 0.25 ml of plasma.,Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338182/),[ng] / [ml],5,16370,DB00736,Esomeprazole
,16338182,limit of quantification (LOQ),The limit of quantification (LOQ) achieved with this method was 5 ng/ml for 5-hydroxyomeprazole and 10 ng/ml for omeprazole and omeprazole-sulfone using 0.25 ml of plasma.,Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338182/),[ng] / [ml],10,16371,DB00736,Esomeprazole
,28407418,bioavailability,"The bioavailability of esomeprazole administered as PO enteric-coated granules and as SC injections was 71.4 and 106%, respectively.","Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28407418/),%,71.4,21132,DB00736,Esomeprazole
,28407418,bioavailability,"The bioavailability of esomeprazole administered as PO enteric-coated granules and as SC injections was 71.4 and 106%, respectively.","Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28407418/),%,106,21133,DB00736,Esomeprazole
,28407418,half-life,The half-life was approximately 1 hour.,"Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28407418/),h,1,21134,DB00736,Esomeprazole
,22832034,AUC(τ),"The mean AUC(τ) ranged from 6.9 μmol · h/L (10 mg, 6-11 years) to 17.6 μmol · h/L (40 mg, 12-17 years).","Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832034/),[h·μM] / [l],6.9,26242,DB00736,Esomeprazole
,22832034,AUC(τ),"The mean AUC(τ) ranged from 6.9 μmol · h/L (10 mg, 6-11 years) to 17.6 μmol · h/L (40 mg, 12-17 years).","Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832034/),[h·μM] / [l],17.6,26243,DB00736,Esomeprazole
,22832034,"C(ss,max)","The mean C(ss,max) ranged from 3.7 μmol/L (0.5 mg/kg, 0-1 month) to 10.5 μmol/L (40 mg, 12-17 years).","Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832034/),[μM] / [l],3.7,26244,DB00736,Esomeprazole
,22832034,"C(ss,max)","The mean C(ss,max) ranged from 3.7 μmol/L (0.5 mg/kg, 0-1 month) to 10.5 μmol/L (40 mg, 12-17 years).","Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832034/),[μM] / [l],10.5,26245,DB00736,Esomeprazole
,30030850,Rs,"Satisfactory resolution (Rs = 2.0) was achieved within 7.3 min on a Chiralpak ID column (250 × 4.6 mm, 5 μm) employing acetonitrile-water (60:40, v/v) as the mobile phase at a flow rate of 0.6 mL/min.",Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30030850/),,2.0,27316,DB00736,Esomeprazole
,30030850,flow rate,"Satisfactory resolution (Rs = 2.0) was achieved within 7.3 min on a Chiralpak ID column (250 × 4.6 mm, 5 μm) employing acetonitrile-water (60:40, v/v) as the mobile phase at a flow rate of 0.6 mL/min.",Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30030850/),[ml] / [min],0.6,27317,DB00736,Esomeprazole
,11984146,maximum plasma concentration (Cmax),"Esomeprazole was absorbed rapidly (mean maximum plasma concentration (Cmax) 6.1 micromol/l, mean time to Cmax (tmax) 1.9 h) and eliminated rapidly (mean plasma elimination half-life (t1/2) 2.1 h).",Pharmacokinetic study of esomeprazole in patients with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11984146/),[μM] / [l],6.1,28385,DB00736,Esomeprazole
,11984146,time to Cmax (tmax),"Esomeprazole was absorbed rapidly (mean maximum plasma concentration (Cmax) 6.1 micromol/l, mean time to Cmax (tmax) 1.9 h) and eliminated rapidly (mean plasma elimination half-life (t1/2) 2.1 h).",Pharmacokinetic study of esomeprazole in patients with hepatic impairment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11984146/),h,1.9,28386,DB00736,Esomeprazole
,11984146,plasma elimination half-life (t1/2),"Esomeprazole was absorbed rapidly (mean maximum plasma concentration (Cmax) 6.1 micromol/l, mean time to Cmax (tmax) 1.9 h) and eliminated rapidly (mean plasma elimination half-life (t1/2) 2.1 h).",Pharmacokinetic study of esomeprazole in patients with hepatic impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11984146/),h,2.1,28387,DB00736,Esomeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.38,37476,DB00736,Esomeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.15,37477,DB00736,Esomeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.13,37478,DB00736,Esomeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.05,37479,DB00736,Esomeprazole
,28801980,IC50,"Moreover, in vitro experiments demonstrated that PPIs (esomeprazole, lansoprazole, omeprazole and rabeprazole) inhibited hOAT3-mediated uptake of MTX in a concentration-dependent manner (IC50 values of 0.40-5.5 μ m), with a rank order of lansoprazole > esomeprazole > rabeprazole > omeprazole.",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),m·μ,0.40-5.5,37480,DB00736,Esomeprazole
,17617287,Reconstitution time,Reconstitution time was 2 minutes with water and 9 to 10 minutes with apple or orange juice.,A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617287/),min,2,40481,DB00736,Esomeprazole
,17617287,Reconstitution time,Reconstitution time was 2 minutes with water and 9 to 10 minutes with apple or orange juice.,A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617287/),min,9 to 10,40482,DB00736,Esomeprazole
,18076214,elimination half-lives,The currently available PPIs have short elimination half-lives ranging from 1 to 1.5 hours.,Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076214/),h,1 to 1.5,42062,DB00736,Esomeprazole
,27121938,bioavailability,"Esomeprazole treatment resulted in decreased lapatinib bioavailability (mean 26%, range 6-49%) that was inversely associated with patient age as a significant covariate.",Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121938/),%,26,44928,DB00736,Esomeprazole
,31332820,percentages time,The mean percentages time of intragastric pH >6 was 63.6 and 51.7% for healthy subjects after receiving ilaprazole 30 mg and esomeprazole 80 mg.,"Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31332820/),%,63.6,45365,DB00736,Esomeprazole
,31332820,percentages time,The mean percentages time of intragastric pH >6 was 63.6 and 51.7% for healthy subjects after receiving ilaprazole 30 mg and esomeprazole 80 mg.,"Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31332820/),%,51.7,45366,DB00736,Esomeprazole
,24892629,relative bioavailability,The optimal formulation achieved good SR feature both in vitro and in vivo with a relative bioavailability of 103.50%.,Preparation and in vitro/in vivo evaluation of esomeprazole magnesium-modified release pellets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892629/),%,103.50,48106,DB00736,Esomeprazole
,30216801,VRC,"Interestingly, patients in the PPIs groups were more likely to reach the therapeutic VRC range of 1-5.5 μg/mL in steady state when compared with control patients (75-81% VS 69%).",The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30216801/),[μg] / [ml],1-5.5,56720,DB00736,Esomeprazole
,25922056,limit of detection (LOD),"The DESI-MS/MS method exhibited for the esomepazole excellent sensitivity (limit of detection (LOD)=60 ng/mL), linearity (0.2-20 µg/mL concentration range; y=23848(±361)X, n=15; r(2) =0.987) and precision (RSD<9%) by using an internal standard method.",Development and validation of a DESI-HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25922056/),[ng] / [ml],60,63839,DB00736,Esomeprazole
,18030229,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 micromol x h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030229/),[h·μM] / [l],0.24,64004,DB00736,Esomeprazole
,18030229,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 micromol x h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030229/),[h·μM] / [l],1.79,64005,DB00736,Esomeprazole
,26902772,mean residence time,"In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h).",Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902772/),h,7.55,65732,DB00736,Esomeprazole
,26902772,mean residence time,"In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h).",Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902772/),h,1.46,65733,DB00736,Esomeprazole
,22108788,Plasma concentrations,"Plasma concentrations of voriconazole and methadone were high, 12.4 mg/l (therapeutic range: 1-4 mg/l) and 1.6 mg/l (therapeutic range: 0.2-0.4 mg/l), respectively.","Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108788/),[mg] / [l],12.4,66152,DB00736,Esomeprazole
,22108788,Plasma concentrations,"Plasma concentrations of voriconazole and methadone were high, 12.4 mg/l (therapeutic range: 1-4 mg/l) and 1.6 mg/l (therapeutic range: 0.2-0.4 mg/l), respectively.","Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108788/),[mg] / [l],1.6,66153,DB00736,Esomeprazole
,20678688,C(max),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [l],5.26,73389,DB00736,Esomeprazole
,20678688,C(max),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [l],5.54,73390,DB00736,Esomeprazole
,20678688,T(max),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),h,2.53,73391,DB00736,Esomeprazole
,20678688,T(max),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),h,2.07,73392,DB00736,Esomeprazole
,20678688,AUC(0-12),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [h·l],15.74,73393,DB00736,Esomeprazole
,20678688,AUC(0-12),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [h·l],16.68,73394,DB00736,Esomeprazole
,20678688,AUC(0-infinity),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [h·l],17.15,73395,DB00736,Esomeprazole
,20678688,AUC(0-infinity),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [h·l],18.26,73396,DB00736,Esomeprazole
,20678688,T(max),"The mean T(max) was found to be significantly different between the test and reference formulations (2.53 [0.67] vs 2.07 [0.65] hours, respectively; P < 0.05).","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),h,2.53,73397,DB00736,Esomeprazole
,20678688,T(max),"The mean T(max) was found to be significantly different between the test and reference formulations (2.53 [0.67] vs 2.07 [0.65] hours, respectively; P < 0.05).","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),h,2.07,73398,DB00736,Esomeprazole
,27345284,tmax,Median tmax was 5 hours with food and 3 hours under fasted conditions.,"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27345284/),h,5,89865,DB00736,Esomeprazole
,27345284,tmax,Median tmax was 5 hours with food and 3 hours under fasted conditions.,"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27345284/),h,3,89866,DB00736,Esomeprazole
,11286324,plasma AUCinfinity,"On day 5, the mean plasma AUCinfinity of esomeprazole was 16.0 micromol x h/L, Cmax was 5.6 micromol/L, tmax was 1.5 hours and t(1/2z) was 1.7 hours.",Pharmacokinetic study of esomeprazole in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286324/),[h·μM] / [l],16.0,90241,DB00736,Esomeprazole
,11286324,Cmax,"On day 5, the mean plasma AUCinfinity of esomeprazole was 16.0 micromol x h/L, Cmax was 5.6 micromol/L, tmax was 1.5 hours and t(1/2z) was 1.7 hours.",Pharmacokinetic study of esomeprazole in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286324/),[μM] / [l],5.6,90242,DB00736,Esomeprazole
,11286324,tmax,"On day 5, the mean plasma AUCinfinity of esomeprazole was 16.0 micromol x h/L, Cmax was 5.6 micromol/L, tmax was 1.5 hours and t(1/2z) was 1.7 hours.",Pharmacokinetic study of esomeprazole in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286324/),h,1.5,90243,DB00736,Esomeprazole
,11286324,t(1/2z),"On day 5, the mean plasma AUCinfinity of esomeprazole was 16.0 micromol x h/L, Cmax was 5.6 micromol/L, tmax was 1.5 hours and t(1/2z) was 1.7 hours.",Pharmacokinetic study of esomeprazole in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286324/),h,1.7,90244,DB00736,Esomeprazole
,32780750,injection flow,"Separation of naproxen and its major metabolic products will be performed using a Shim-Pack XR-ODS 75Lx2.0 column and C18 pre-column (Shimadzu, Kyoto, Japan) at 40°C using a mixture of methanol and 10 mM ammonium acetate (70:30, v/v) with an injection flow of 0.3 mL/min.",Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32780750/),[ml] / [min],0.3,96951,DB00736,Esomeprazole
,32780750,total analytical run time,The total analytical run time will be 5 min.,Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32780750/),min,5,96952,DB00736,Esomeprazole
,21455427,AUC(0-24),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,22.78,113108,DB00736,Esomeprazole
,21455427,AUC(0-24),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,10.46,113109,DB00736,Esomeprazole
,21455427,C(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,2.76,113110,DB00736,Esomeprazole
,21455427,C(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,1.412,113111,DB00736,Esomeprazole
,21455427,T(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,2.83,113112,DB00736,Esomeprazole
,21455427,T(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,3,113113,DB00736,Esomeprazole
,26257511,Cmax,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[μg] / [ml],61.67,113794,DB00736,Esomeprazole
,26257511,Cmax,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[μg] / [ml],61.85,113795,DB00736,Esomeprazole
,26257511,AUC0-t,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·μg] / [ml],"1,206.52",113796,DB00736,Esomeprazole
,26257511,AUC0-t,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·μg] / [ml],"1,211.44",113797,DB00736,Esomeprazole
,26257511,Cmax,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[ng] / [ml],658.21,113798,DB00736,Esomeprazole
,26257511,Cmax,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[ng] / [ml],595.09,113799,DB00736,Esomeprazole
,26257511,AUC0-t,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·ng] / [ml],"1,109.11",113800,DB00736,Esomeprazole
,26257511,AUC0-t,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·ng] / [ml],"1,015.12",113801,DB00736,Esomeprazole
,19394048,area under the plasma concentration time curve,"The estimated geometric mean of area under the plasma concentration time curve during the dosing interval and observed maximum plasma concentration was 2.5 micromol x h/L and 0.74 micromol/L, respectively.",Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19394048/),[h·μM] / [l],2.5,128679,DB00736,Esomeprazole
,19394048,observed maximum plasma concentration,"The estimated geometric mean of area under the plasma concentration time curve during the dosing interval and observed maximum plasma concentration was 2.5 micromol x h/L and 0.74 micromol/L, respectively.",Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19394048/),[h·μM] / [l],2.5,128680,DB00736,Esomeprazole
,19394048,observed maximum plasma concentration,"The estimated geometric mean of area under the plasma concentration time curve during the dosing interval and observed maximum plasma concentration was 2.5 micromol x h/L and 0.74 micromol/L, respectively.",Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19394048/),[μM] / [l],0.74,128681,DB00736,Esomeprazole
,23719968,total clearance (CL),"The mean values (% relative standard error) for total clearance (CL) and for central volume of distribution (Vd) in patients with and without concomitant esomeprazole were 5.3 L/h (9.2 %) and 256.1 (6.4 %) and 153.2 l (19.2 %), respectively.",Interaction of thiopental with esomeprazole in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719968/),[l] / [h],5.3,129978,DB00736,Esomeprazole
,23719968,central volume of distribution (Vd),"The mean values (% relative standard error) for total clearance (CL) and for central volume of distribution (Vd) in patients with and without concomitant esomeprazole were 5.3 L/h (9.2 %) and 256.1 (6.4 %) and 153.2 l (19.2 %), respectively.",Interaction of thiopental with esomeprazole in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719968/),l,153.2,129979,DB00736,Esomeprazole
,30520273,clearance (CL) ratio,The predicted-to-observed pantoprazole clearance (CL) ratio ranged from 0.96-1.35 in children 1-17 years of age and 0.43-0.70 in term infants.,Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.96-1.35,135347,DB00736,Esomeprazole
,30520273,clearance (CL) ratio,The predicted-to-observed pantoprazole clearance (CL) ratio ranged from 0.96-1.35 in children 1-17 years of age and 0.43-0.70 in term infants.,Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.43-0.70,135348,DB00736,Esomeprazole
,30520273,CL ratio,"The predicted-to-observed esomeprazole CL ratio ranged from 1.08-1.50 for children 6-17 years of age, and 0.15-0.33 for infants.",Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,1.08-1.50,135349,DB00736,Esomeprazole
,30520273,CL ratio,"The predicted-to-observed esomeprazole CL ratio ranged from 1.08-1.50 for children 6-17 years of age, and 0.15-0.33 for infants.",Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.15-0.33,135350,DB00736,Esomeprazole
,26422094,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 μmol · h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26422094/),[h·μM] / [l],0.24,145889,DB00736,Esomeprazole
,26422094,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 μmol · h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26422094/),[h·μM] / [l],1.79,145890,DB00736,Esomeprazole
,31564831,Time to peak concentration,Time to peak concentration of IR-ESO (0.50-0.75 hr) was shorter than that of ESO (1.25-1.50 hr).,"The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564831/),h,0.50-0.75,151663,DB00736,Esomeprazole
,31564831,Time to peak concentration,Time to peak concentration of IR-ESO (0.50-0.75 hr) was shorter than that of ESO (1.25-1.50 hr).,"The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564831/),h,1.25-1.50,151664,DB00736,Esomeprazole
,31564831,time to maintain gastric pH >4,"In addition, mean time to maintain gastric pH >4 for 24 hr was similar for both drugs (IR-ESO 55.5-69.9% vs ESO 56.8-70.2%).","The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564831/),,24,151665,DB00736,Esomeprazole
,16750456,AUC(0-infinity),Geometric mean AUC(0-infinity) values (overall drug exposure) were 1.58 and 5.57 micromol .,"Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),μM,1.58,155992,DB00736,Esomeprazole
,16750456,AUC(0-infinity),Geometric mean AUC(0-infinity) values (overall drug exposure) were 1.58 and 5.57 micromol .,"Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),μM,5.57,155993,DB00736,Esomeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[μM] / [l],0.67,155994,DB00736,Esomeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[μM] / [l],2.78,155995,DB00736,Esomeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[l·μM] / [kg],0.012,155996,DB00736,Esomeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[l·μM] / [kg],0.041,155997,DB00736,Esomeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[μM] / [l],1.45,155998,DB00736,Esomeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[μM] / [l],5.13,155999,DB00736,Esomeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[l·μM] / [kg],0.026,156000,DB00736,Esomeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[l·μM] / [kg],0.075,156001,DB00736,Esomeprazole
,32558923,turnover half-life,"Based on the recovery of R-pantoprazole oral clearance, the turnover half-life of CYP2C19 was estimated to average 53 hours.","Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558923/),h,53,159396,DB00736,Esomeprazole
,21628602,t(max),"Naproxen plasma profiles were similar between the NAP/ESO tablet and EC naproxen, although median t(max) was longest for the NAP/ESO tablet (5.3 vs 3.5-4.0 hours).",Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,5.3,160356,DB00736,Esomeprazole
,21628602,t(max),"Naproxen plasma profiles were similar between the NAP/ESO tablet and EC naproxen, although median t(max) was longest for the NAP/ESO tablet (5.3 vs 3.5-4.0 hours).",Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,3.5-4.0,160357,DB00736,Esomeprazole
,21628602,t(max),The NAP/ESO tablet produced much shorter esomeprazole t(max) than the EC esomeprazole formulation (0.45 vs 2.5 hours).,Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,0.45,160358,DB00736,Esomeprazole
,21628602,t(max),The NAP/ESO tablet produced much shorter esomeprazole t(max) than the EC esomeprazole formulation (0.45 vs 2.5 hours).,Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,2.5,160359,DB00736,Esomeprazole
,11214773,Plasma clearance (CL),"Plasma clearance (CL) of esomeprazole decreased from 22 l/h to 16 l/h and from 17 l/h to 9 l/h following repeated dosing of 20 mg and 40 mg, respectively.",Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[l] / [h],22,163709,DB00736,Esomeprazole
,11214773,Plasma clearance (CL),"Plasma clearance (CL) of esomeprazole decreased from 22 l/h to 16 l/h and from 17 l/h to 9 l/h following repeated dosing of 20 mg and 40 mg, respectively.",Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[l] / [h],16,163710,DB00736,Esomeprazole
,11214773,Plasma clearance (CL),"Plasma clearance (CL) of esomeprazole decreased from 22 l/h to 16 l/h and from 17 l/h to 9 l/h following repeated dosing of 20 mg and 40 mg, respectively.",Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[l] / [h],17,163711,DB00736,Esomeprazole
,11214773,Plasma clearance (CL),"Plasma clearance (CL) of esomeprazole decreased from 22 l/h to 16 l/h and from 17 l/h to 9 l/h following repeated dosing of 20 mg and 40 mg, respectively.",Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[l] / [h],9,163712,DB00736,Esomeprazole
,11214773,Total area under the plasma concentration-time curve (AUC),Total area under the plasma concentration-time curve (AUC) increased (from 1.34 micromol x h/l to 2.55 micromol x h/l) with absolute bioavailability (F) being 50% on day 1 and 68% on day 5 after the 20-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[h·μM] / [l],1.34,163713,DB00736,Esomeprazole
,11214773,Total area under the plasma concentration-time curve (AUC),Total area under the plasma concentration-time curve (AUC) increased (from 1.34 micromol x h/l to 2.55 micromol x h/l) with absolute bioavailability (F) being 50% on day 1 and 68% on day 5 after the 20-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[h·μM] / [l],2.55,163714,DB00736,Esomeprazole
,11214773,absolute bioavailability (F),Total area under the plasma concentration-time curve (AUC) increased (from 1.34 micromol x h/l to 2.55 micromol x h/l) with absolute bioavailability (F) being 50% on day 1 and 68% on day 5 after the 20-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),%,50,163715,DB00736,Esomeprazole
,11214773,absolute bioavailability (F),Total area under the plasma concentration-time curve (AUC) increased (from 1.34 micromol x h/l to 2.55 micromol x h/l) with absolute bioavailability (F) being 50% on day 1 and 68% on day 5 after the 20-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),%,68,163716,DB00736,Esomeprazole
,11214773,AUC,AUC increased (from 4.32 micromol x h/l to 11.21 micromol x h/l) with F being 64% on day 1 and 89% on day 5 after the 40-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[h·μM] / [l],4.32,163717,DB00736,Esomeprazole
,11214773,AUC,AUC increased (from 4.32 micromol x h/l to 11.21 micromol x h/l) with F being 64% on day 1 and 89% on day 5 after the 40-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[h·μM] / [l],11.21,163718,DB00736,Esomeprazole
,21696537,area under the,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,54,166599,DB00736,Esomeprazole
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,66.3,166600,DB00736,Esomeprazole
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,47,166601,DB00736,Esomeprazole
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,59.7,166602,DB00736,Esomeprazole
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,68.9,166603,DB00736,Esomeprazole
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,64.5,166604,DB00736,Esomeprazole
,31251331,flow rate,The flow rate was 1 mL/min and maximum absorption was measured using Diode Array (DAD) detector at 285 nm.,"Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[ml] / [min],1,174358,DB00736,Esomeprazole
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,2.68,174359,DB00736,Esomeprazole
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,3.52,174360,DB00736,Esomeprazole
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,5.17,174361,DB00736,Esomeprazole
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.10,174362,DB00736,Esomeprazole
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.07,174363,DB00736,Esomeprazole
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.04,174364,DB00736,Esomeprazole
,11768559,half-life,"Actually, all PPIs display chemical activation half-lives at pH 1.0 of a few minutes at the most, while being eliminated from serum with a half-life of about 1 h.",Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11768559/),h,1,175782,DB00736,Esomeprazole
,30422368,time to reach maximum plasma concentration,"Esomeprazole was absorbed and eliminated rapidly in all groups, with a median time to reach maximum plasma concentration of 1.47-1.75 h, an arithmetic mean terminal elimination half-life of 0.80-1.37 h, and a weight-correlated apparent total body clearance of 0.216-0.343 L/h/kg.","Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30422368/),h,1.47-1.75,176105,DB00736,Esomeprazole
,30422368,terminal elimination half-life,"Esomeprazole was absorbed and eliminated rapidly in all groups, with a median time to reach maximum plasma concentration of 1.47-1.75 h, an arithmetic mean terminal elimination half-life of 0.80-1.37 h, and a weight-correlated apparent total body clearance of 0.216-0.343 L/h/kg.","Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30422368/),h,0.80-1.37,176106,DB00736,Esomeprazole
,30422368,weight-correlated apparent total body clearance,"Esomeprazole was absorbed and eliminated rapidly in all groups, with a median time to reach maximum plasma concentration of 1.47-1.75 h, an arithmetic mean terminal elimination half-life of 0.80-1.37 h, and a weight-correlated apparent total body clearance of 0.216-0.343 L/h/kg.","Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30422368/),[l] / [h·kg],0.216-0.343,176107,DB00736,Esomeprazole
,17213007,AUC(0-infinity),"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·pM] / [l],4.83,182691,DB00736,Esomeprazole
,17213007,AUC(0-infinity),"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·pM] / [l],0.74,182692,DB00736,Esomeprazole
,17213007,AUC(0-infinity),"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·μM] / [kg·l],0.32,182693,DB00736,Esomeprazole
,17213007,AUC(0-infinity),"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·μM] / [kg·l],0.04,182694,DB00736,Esomeprazole
,17213007,Cmax,"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [l],2.98,182695,DB00736,Esomeprazole
,17213007,Cmax,"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [l],0.62,182696,DB00736,Esomeprazole
,17213007,Cmax,"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[l·μM] / [kg],0.19,182697,DB00736,Esomeprazole
,17213007,Cmax,"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[l·μM] / [kg],0.03,182698,DB00736,Esomeprazole
,17213007,AUC(0-infinity),"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·μM] / [l],6.28,182699,DB00736,Esomeprazole
,17213007,AUC(0-infinity),"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·μM] / [l],3.70,182700,DB00736,Esomeprazole
,17213007,AUC(0-infinity),"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·pM] / [kg·l],0.21,182701,DB00736,Esomeprazole
,17213007,AUC(0-infinity),"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·pM] / [kg·l],0.12,182702,DB00736,Esomeprazole
,17213007,Cmax,"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [l],3.73,182703,DB00736,Esomeprazole
,17213007,Cmax,"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [l],1.77,182704,DB00736,Esomeprazole
,17213007,Cmax,"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [1·kg·l],0.13,182705,DB00736,Esomeprazole
,17213007,Cmax,"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [1·kg·l],0.06,182706,DB00736,Esomeprazole
,17213007,body-weight-normalized apparent oral clearance,"For the 10-mg esomeprazole dose, the geometric mean body-weight-normalized apparent oral clearance was approximately 50% higher in the younger group compared with the older group (0.40 and 0.25 L/h x kg(-1), respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·l] / [kg],0.40,182707,DB00736,Esomeprazole
,17213007,body-weight-normalized apparent oral clearance,"For the 10-mg esomeprazole dose, the geometric mean body-weight-normalized apparent oral clearance was approximately 50% higher in the younger group compared with the older group (0.40 and 0.25 L/h x kg(-1), respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·l] / [kg],0.25,182708,DB00736,Esomeprazole
,23545593,half-life,"The VRZ half-life, calculated to 58 h in this patient, was by far higher than the values reported in the literature.",A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545593/),h,58,182752,DB00736,Esomeprazole
,26071277,Emax,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),%,56,183118,DB00736,Esomeprazole
,26071277,EAUC50,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),[h·μg] / [l],15.9,183119,DB00736,Esomeprazole
,27734291,terminal plasma half-life,Cabozantinib displays a long terminal plasma half-life (~120 h) and accumulates ~fivefold by day 15 following daily dosing based on area under the plasma concentration-time curve (AUC).,Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734291/),h,120,185601,DB00736,Esomeprazole
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],55.9,186198,DB00736,Esomeprazole
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],53.7,186199,DB00736,Esomeprazole
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],53.6,186200,DB00736,Esomeprazole
,29403981,flow rate,The flow rate was set at 0.5 mL/min to elute all the analytes and IS within 1.00 min runtime.,"Development and validation of a high throughput UPLC-MS/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403981/),[ml] / [min],0.5,188171,DB00736,Esomeprazole
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,231.2,193838,DB00736,Esomeprazole
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,346.9,193839,DB00736,Esomeprazole
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,285.1,193840,DB00736,Esomeprazole
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,382.2,193841,DB00736,Esomeprazole
,15871633,time to reach maximum plasma concentration,"Like adults, PPIs are rapidly absorbed in children following oral administration; the mean time to reach maximum plasma concentration varies from 1 to 3 hours.",Pharmacokinetics of proton pump inhibitors in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1 to 3,196990,DB00736,Esomeprazole
,15871633,elimination half-lives,"PPIs are rapidly metabolised in children, with short elimination half-lives of around 1 hour, similar to that reported for adults.",Pharmacokinetics of proton pump inhibitors in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1,196991,DB00736,Esomeprazole
,23512128,half-life,"After irreversible chemical inhibition of the proton pump, such as occurs with pantoprazole, the recovery of the protein of the pump has a half-life of around 50 h.","Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23512128/),h,50,198226,DB00736,Esomeprazole
,26121346,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 μmol · h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26121346/),[h·μM] / [l],0.24,200305,DB00736,Esomeprazole
,26121346,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 μmol · h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26121346/),[h·μM] / [l],1.79,200306,DB00736,Esomeprazole
,25250612,AUC(0-∞),"Children weighing 8 - < 20 kg had a 1.8-fold higher exposure with the 10-mg vs. 5-mg dose (AUC(0-∞), 1.32 vs.","Single-dose pharmacokinetic properties of esomeprazole in children aged 1 - 11 years with endoscopically proven GERD: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25250612/),,1.32,206504,DB00736,Esomeprazole
,25250612,AUC(0-∞),"0.73 μmol·h/L, respectively); children weighing ≥ 20 kg had a 4.4-fold higher exposure with the 20-mg vs. 10-mg dose (AUC(0-∞), 3.06 vs. 0.69 μmol·h/L).","Single-dose pharmacokinetic properties of esomeprazole in children aged 1 - 11 years with endoscopically proven GERD: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25250612/),[h·μM] / [l],3.06,206505,DB00736,Esomeprazole
,25250612,AUC(0-∞),"0.73 μmol·h/L, respectively); children weighing ≥ 20 kg had a 4.4-fold higher exposure with the 20-mg vs. 10-mg dose (AUC(0-∞), 3.06 vs. 0.69 μmol·h/L).","Single-dose pharmacokinetic properties of esomeprazole in children aged 1 - 11 years with endoscopically proven GERD: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25250612/),[h·μM] / [l],0.69,206506,DB00736,Esomeprazole
,15578172,total area under the plasma concentration-time curve (AUC),"Following the 20-mg dose of each compound, values of the total area under the plasma concentration-time curve (AUC) were 1.52, 0.62 and 1.04 micromol h/l for S-omeprazole, R-omeprazole and racemic omeprazole, respectively, on day 1.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],1.52,214276,DB00736,Esomeprazole
,15578172,total area under the plasma concentration-time curve (AUC),"Following the 20-mg dose of each compound, values of the total area under the plasma concentration-time curve (AUC) were 1.52, 0.62 and 1.04 micromol h/l for S-omeprazole, R-omeprazole and racemic omeprazole, respectively, on day 1.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],0.62,214277,DB00736,Esomeprazole
,15578172,total area under the plasma concentration-time curve (AUC),"Following the 20-mg dose of each compound, values of the total area under the plasma concentration-time curve (AUC) were 1.52, 0.62 and 1.04 micromol h/l for S-omeprazole, R-omeprazole and racemic omeprazole, respectively, on day 1.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],1.04,214278,DB00736,Esomeprazole
,15578172,AUC,"Respectively, AUC values on day 5 were 2.84, 0.68 and 1.63 micromol h/l.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],2.84,214279,DB00736,Esomeprazole
,15578172,AUC,"Respectively, AUC values on day 5 were 2.84, 0.68 and 1.63 micromol h/l.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],0.68,214280,DB00736,Esomeprazole
,15578172,AUC,"Respectively, AUC values on day 5 were 2.84, 0.68 and 1.63 micromol h/l.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],1.63,214281,DB00736,Esomeprazole
,30548689,MPTs,"The MPTs for which intragastric pH was ≥3 and ≥4 for 48 hours were 88% ± 7% and 81% ± 9% for the 0.5 mg/kg group and 90% ± 9% and 85% ± 11% for the 1 mg/kg group, respectively, with no significant intergroup differences.",Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30548689/),%,88,215518,DB00736,Esomeprazole
,30548689,MPTs,"The MPTs for which intragastric pH was ≥3 and ≥4 for 48 hours were 88% ± 7% and 81% ± 9% for the 0.5 mg/kg group and 90% ± 9% and 85% ± 11% for the 1 mg/kg group, respectively, with no significant intergroup differences.",Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30548689/),%,81,215519,DB00736,Esomeprazole
,30548689,MPTs,"The MPTs for which intragastric pH was ≥3 and ≥4 for 48 hours were 88% ± 7% and 81% ± 9% for the 0.5 mg/kg group and 90% ± 9% and 85% ± 11% for the 1 mg/kg group, respectively, with no significant intergroup differences.",Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30548689/),%,90,215520,DB00736,Esomeprazole
,30548689,MPTs,"The MPTs for which intragastric pH was ≥3 and ≥4 for 48 hours were 88% ± 7% and 81% ± 9% for the 0.5 mg/kg group and 90% ± 9% and 85% ± 11% for the 1 mg/kg group, respectively, with no significant intergroup differences.",Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30548689/),%,85,215521,DB00736,Esomeprazole
,32227647,apparent clearance,"The apparent clearance at 10-mg dose was 17.32, 9.77 and 7.37 (L/h) for homozygous extensive metabolizer, heterozygous extensive metabolizer and poor metabolizer subjects, respectively.",Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32227647/),[l] / [h],17.32,225083,DB00736,Esomeprazole
,32227647,apparent clearance,"The apparent clearance at 10-mg dose was 17.32, 9.77 and 7.37 (L/h) for homozygous extensive metabolizer, heterozygous extensive metabolizer and poor metabolizer subjects, respectively.",Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32227647/),[l] / [h],9.77,225084,DB00736,Esomeprazole
,32227647,apparent clearance,"The apparent clearance at 10-mg dose was 17.32, 9.77 and 7.37 (L/h) for homozygous extensive metabolizer, heterozygous extensive metabolizer and poor metabolizer subjects, respectively.",Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32227647/),[l] / [h],7.37,225085,DB00736,Esomeprazole
,30050845,dose-normalized peak plasma concentration (Cmax),"Median (range) dose-normalized peak plasma concentration (Cmax) values for the IV and po formulations were 4.06 µg/mL (2.47-4.57 µg/mL) and 1.04 µg/mL (0.31-1.91 µg/mL), respectively.",Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),[μg] / [ml],4.06,228203,DB00736,Esomeprazole
,30050845,dose-normalized peak plasma concentration (Cmax),"Median (range) dose-normalized peak plasma concentration (Cmax) values for the IV and po formulations were 4.06 µg/mL (2.47-4.57 µg/mL) and 1.04 µg/mL (0.31-1.91 µg/mL), respectively.",Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),[μg] / [ml],1.04,228204,DB00736,Esomeprazole
,30050845,time-to-peak concentration (Tmax),The median (range) time-to-peak concentration (Tmax) for the po formulation was 105 minutes (45-360 minutes).,Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),min,105,228205,DB00736,Esomeprazole
,30050845,plasma terminal half-life (t½),Median (range) plasma terminal half-life (t½) was 45.56 minutes (39.43-64.20 minutes) for the IV formulation and 63.97 minutes (44.02-109.94 minutes) for the enteric-coated po formulation.,Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),min,45.56,228206,DB00736,Esomeprazole
,30050845,plasma terminal half-life (t½),Median (range) plasma terminal half-life (t½) was 45.56 minutes (39.43-64.20 minutes) for the IV formulation and 63.97 minutes (44.02-109.94 minutes) for the enteric-coated po formulation.,Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),min,63.97,228207,DB00736,Esomeprazole
,30050845,bioavailability,The median (range) po bioavailability was 63.33% (32.26%-79.77%).,Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),%,63.33,228208,DB00736,Esomeprazole
,20015104,pH,"On day 5, median pH (5.34 +/- 0.45 and 5.19 +/- 0.52 vs.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,5.34,229709,DB00736,Esomeprazole
,20015104,pH,"On day 5, median pH (5.34 +/- 0.45 and 5.19 +/- 0.52 vs.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,5.19,229710,DB00736,Esomeprazole
,20015104,percentage time,"4.76 +/- 0.82, respectively, P < 0.002) and percentage time with pH > 4 (80 +/- 11 and 77 +/- 12, vs. 63 +/- 11 respectively, P < 0.0001) for 24-h were higher with S-tenatoprazole-Na 90 mg and 60 mg than esomeprazole.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,80,229711,DB00736,Esomeprazole
,20015104,percentage time,"4.76 +/- 0.82, respectively, P < 0.002) and percentage time with pH > 4 (80 +/- 11 and 77 +/- 12, vs. 63 +/- 11 respectively, P < 0.0001) for 24-h were higher with S-tenatoprazole-Na 90 mg and 60 mg than esomeprazole.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,77,229712,DB00736,Esomeprazole
,20015104,percentage time,"4.76 +/- 0.82, respectively, P < 0.002) and percentage time with pH > 4 (80 +/- 11 and 77 +/- 12, vs. 63 +/- 11 respectively, P < 0.0001) for 24-h were higher with S-tenatoprazole-Na 90 mg and 60 mg than esomeprazole.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,63,229713,DB00736,Esomeprazole
,20015104,percentage,"In nocturnal periods, S-tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001).","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,77,229714,DB00736,Esomeprazole
,20015104,percentage,"In nocturnal periods, S-tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001).","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,73,229715,DB00736,Esomeprazole
,20015104,percentage,"In nocturnal periods, S-tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001).","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,64,229716,DB00736,Esomeprazole
,20015104,percentage,"In nocturnal periods, S-tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001).","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,46,229717,DB00736,Esomeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,15,231478,DB00736,Esomeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,29,231479,DB00736,Esomeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,46,231480,DB00736,Esomeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,28,231481,DB00736,Esomeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,62,231482,DB00736,Esomeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,90,231483,DB00736,Esomeprazole
,11563995,inhibition,The mean inhibition values of the pentagastrin-stimulated peak acid output for omeprazole were 35% (day 1) to 79% (day 5).,"Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),,35,231484,DB00736,Esomeprazole
,11563995,inhibition,The mean inhibition values of the pentagastrin-stimulated peak acid output for omeprazole were 35% (day 1) to 79% (day 5).,"Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),,79,231485,DB00736,Esomeprazole
,23110788,tmax,"Co-administration of esomeprazole decreased geometric mean Cmax of ulipristal acetate by 65% (geometric mean ratio point estimate (90% CI): 0.35 (0.28 - 0.42)), and delayed median tmax from 0.75 to 1.00 h (Hodges-Lehmann estimate of difference (90% CI): tmax 0.63 (0.25 - 1.25)) but had minor effects on AUCs of +15% and +11% (geometric mean ratio point estimates (90% CI): AUC0-t 1.15 (1.02 - 1.31) and AUC0-∞ (1.11 (0.98 - 1.27)), respectively.",Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110788/),h,0.75,238667,DB00736,Esomeprazole
,23110788,tmax,"Co-administration of esomeprazole decreased geometric mean Cmax of ulipristal acetate by 65% (geometric mean ratio point estimate (90% CI): 0.35 (0.28 - 0.42)), and delayed median tmax from 0.75 to 1.00 h (Hodges-Lehmann estimate of difference (90% CI): tmax 0.63 (0.25 - 1.25)) but had minor effects on AUCs of +15% and +11% (geometric mean ratio point estimates (90% CI): AUC0-t 1.15 (1.02 - 1.31) and AUC0-∞ (1.11 (0.98 - 1.27)), respectively.",Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110788/),h,1.00,238668,DB00736,Esomeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,84.2,249470,DB00736,Esomeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,88.9,249471,DB00736,Esomeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,77.8,249472,DB00736,Esomeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,74.6,249473,DB00736,Esomeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,81.0,249474,DB00736,Esomeprazole
,16550734,area under the plasma concentration-time curve during the dosing interval (AUCtau),Triple therapy with esomeprazole 40 mg increased the area under the plasma concentration-time curve during the dosing interval (AUCtau) from 13.31 micromol x h/l (11.12-15.93) for esomeprazole alone to 22.69 micromol x h/l (18.94-27.17) for triple treatment.,"Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550734/),[h·μM] / [l],13.31,254558,DB00736,Esomeprazole
,16550734,area under the plasma concentration-time curve during the dosing interval (AUCtau),Triple therapy with esomeprazole 40 mg increased the area under the plasma concentration-time curve during the dosing interval (AUCtau) from 13.31 micromol x h/l (11.12-15.93) for esomeprazole alone to 22.69 micromol x h/l (18.94-27.17) for triple treatment.,"Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550734/),[h·μM] / [l],22.69,254559,DB00736,Esomeprazole
,16550734,AUCtau,Respective AUCtau values with esomeprazole 20 mg b.i.d. were 4.97 micromol.h/l (3.97-6.21) and 11.29 micromol x h/l (9.03-14.12).,"Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550734/),[h·μM] / [l],4.97,254560,DB00736,Esomeprazole
,16550734,AUCtau,Respective AUCtau values with esomeprazole 20 mg b.i.d. were 4.97 micromol.h/l (3.97-6.21) and 11.29 micromol x h/l (9.03-14.12).,"Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550734/),[h·μM] / [l],11.29,254561,DB00736,Esomeprazole
,32671657,IC50,"In vitro studies demonstrated that PPIs inhibited rOAT3-mediated uptake of MTX, with estimated IC50 values of 2.1-5.2 μM, and a rank order of esomeprazole ≈ lansoprazole ≈ omeprazole > rabeprazole.",Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671657/),μM,2.1-5.2,258778,DB00736,Esomeprazole
no more,29128277,recovery,"The recovery was no more than 77.06%, and the matrix effect, stability, dilution integrity tests were all satisfied the currently criterion.","A fast, sensitive, and high throughput method for the determination of esomeprazole in dog plasma by UHPLC-MS/MS: Application to formulation development of the compound preparation of esomeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128277/),%,77.06,264504,DB00736,Esomeprazole
